These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


353 related items for PubMed ID: 25018864

  • 1. Cavin-1/PTRF alters prostate cancer cell-derived extracellular vesicle content and internalization to attenuate extracellular vesicle-mediated osteoclastogenesis and osteoblast proliferation.
    Inder KL, Ruelcke JE, Petelin L, Moon H, Choi E, Rae J, Blumenthal A, Hutmacher D, Saunders NA, Stow JL, Parton RG, Hill MM.
    J Extracell Vesicles; 2014; 3():. PubMed ID: 25018864
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Galectin-3 Overrides PTRF/Cavin-1 Reduction of PC3 Prostate Cancer Cell Migration.
    Meng F, Joshi B, Nabi IR.
    PLoS One; 2015; 10(5):e0126056. PubMed ID: 25942420
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. PTRF/cavin-1 neutralizes non-caveolar caveolin-1 microdomains in prostate cancer.
    Moon H, Lee CS, Inder KL, Sharma S, Choi E, Black DM, Lê Cao KA, Winterford C, Coward JI, Ling MT, Australian Prostate Cancer BioResource, Craik DJ, Parton RG, Russell PJ, Hill MM.
    Oncogene; 2014 Jul 03; 33(27):3561-70. PubMed ID: 23934189
    [Abstract] [Full Text] [Related]

  • 7. Proteomic signatures of extracellular vesicles secreted by nonmineralizing and mineralizing human osteoblasts and stimulation of tumor cell growth.
    Morhayim J, van de Peppel J, Demmers JA, Kocer G, Nigg AL, van Driel M, Chiba H, van Leeuwen JP.
    FASEB J; 2015 Jan 03; 29(1):274-85. PubMed ID: 25359493
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cancer cell invasion alters the protein profile of extracellular vesicles.
    Luoto JC, Coelho-Rato LS, Jungarå C, Bengs SH, Roininen J, Eriksson JE, Sistonen L, Henriksson E.
    J Extracell Biol; 2023 Dec 03; 2(12):e124. PubMed ID: 38938900
    [Abstract] [Full Text] [Related]

  • 10. PTRF/Cavin-1 decreases prostate cancer angiogenesis and lymphangiogenesis.
    Nassar ZD, Moon H, Duong T, Neo L, Hill MM, Francois M, Parton RG, Parat MO.
    Oncotarget; 2013 Oct 03; 4(10):1844-55. PubMed ID: 24123650
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. PTRF-Cavin, a conserved cytoplasmic protein required for caveola formation and function.
    Hill MM, Bastiani M, Luetterforst R, Kirkham M, Kirkham A, Nixon SJ, Walser P, Abankwa D, Oorschot VM, Martin S, Hancock JF, Parton RG.
    Cell; 2008 Jan 11; 132(1):113-24. PubMed ID: 18191225
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Agarose spot migration assay to measure the chemoattractant potential of extracellular vesicles: applications in regenerative medicine and cancer metastasis.
    Clos-Sansalvador M, Monguió-Tortajada M, Grau-Leal F, Ruiz de Porras V, Garcia SG, Sanroque-Muñoz M, Font-Morón M, Franquesa M, Borràs FE.
    BMC Biol; 2023 Oct 26; 21(1):236. PubMed ID: 37884994
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. IL-3R-alpha blockade inhibits tumor endothelial cell-derived extracellular vesicle (EV)-mediated vessel formation by targeting the β-catenin pathway.
    Lombardo G, Gili M, Grange C, Cavallari C, Dentelli P, Togliatto G, Taverna D, Camussi G, Brizzi MF.
    Oncogene; 2018 Mar 26; 37(9):1175-1191. PubMed ID: 29238040
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 18.